Information intended for healthcare professionals only.

The production of this Guidelines card has been commissioned by Novartis Pharmaceuticals UK Ltd. See bottom of page for full disclaimer. Prescribing Information and Adverse Event Reporting can be found here.

Download a PDF of the Guidelines SMC card here

Brolucizumab (Beovu®) SMC22721

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and, following review by the SMC executive, advises NHS Boards and Area Drug and Therapeutics Committees (ADTCs) on its use in NHSScotland.The advice is summarised as follows:

Advice: following a full submission 

brolucizumab (Beovu® is accepted for use within NHSScotland.

Indication under review: in adults for the treatment of neovascular (wet) age-related macular degeneration (AMD).

Non-inferiority of brolucizumab versus another anti-vascular endothelial growth factor medicine was demonstrated for mean change in best corrected visual acuity from baseline to week 48 in two phase III studies in patients with neovascular AMD.

This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/list price that is equivalent or lower. 

About the SMC 

The Scottish Medicines Consortium (SMC) provides advice to NHSScotland about the value for patients of newly licensed medicine. SMC reviews new medicines that have received a licence from the Medicines and Healthcare products Regulatory Agency (MHRA – the licensing body for the UK) or the European Medicines Agency (EMA – the licensing body for the European Union). They also review new formulations of, and new ways to use, established medicines. Before a medicine can be prescribed routinely in Scotland, it has to be accepted for use by SMC. SMC advice helps the health service plan for the quick, uniform introduction of beneficial treatments across NHSScotland. 


1. Scottish Medicines Consortium. brolucizumab (Beovu®) SMC2272. SMC, September 2020.


The production and printing of this Guidelines summary card has been commissioned by Novartis Pharmaceuticals Ltd. Novartis Pharmaceuticals Ltd has reviewed the card for technical accuracy and regulatory compliance and supplied the prescribing information. This summary card only displays the concise guidance; readers are strongly advised to refer to the full guidance at:

The guidance is reproduced with permission of the Scottish Medicines Consortium (SMC). Copyright of the guidance rests with the SMC, and it may be freely reproduced for educational and not-for-profit purposes. No reproduction by, or for, commercial organisations, or for commercial purposes, is allowed without the express written permission of the SMC. 

MGP Ltd owns copyright of the Guidelines brand, logo, and the design and format of this summary card. 

The views and opinions expressed are not necessarily those of Novartis Pharmaceuticals UK Ltd, or of Guidelines, its publisher, advisers, or advertisers. 



BEO20-C089b (1)

Date of preparation: October 2020